Cerus (NASDAQ:CERS) CFO Kevin Dennis Green Sells 55,225 Shares

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 55,225 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $2.06, for a total value of $113,763.50. Following the completion of the sale, the chief financial officer owned 1,195,891 shares in the company, valued at $2,463,535.46. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 6th, Kevin Dennis Green sold 27,796 shares of Cerus stock. The shares were sold at an average price of $2.01, for a total value of $55,869.96.

Cerus Stock Performance

Shares of CERS stock opened at $1.93 on Tuesday. Cerus Corporation has a 52 week low of $1.12 and a 52 week high of $2.96. The company has a market cap of $370.89 million, a P/E ratio of -24.13 and a beta of 1.51. The business has a 50 day moving average of $2.31 and a two-hundred day moving average of $1.86. The company has a quick ratio of 1.17, a current ratio of 1.73 and a debt-to-equity ratio of 0.62.

Cerus (NASDAQ:CERS) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. As a group, analysts anticipate that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Cibc World Markets Corp bought a new stake in Cerus during the 4th quarter valued at $25,000. CIBC Bancorp USA Inc. purchased a new stake in Cerus in the third quarter worth about $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cerus in the 1st quarter worth about $32,000. Aquatic Capital Management LLC purchased a new position in Cerus during the third quarter valued at $35,000. Finally, MML Investors Services LLC bought a new stake in shares of Cerus during the fourth quarter valued at approximately $37,000. 78.37% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CERS has been the subject of several research reports. TD Cowen reaffirmed a “buy” rating on shares of Cerus in a research note on Monday, January 12th. Wall Street Zen downgraded shares of Cerus from a “buy” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold”.

Cerus News Roundup

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Institutional accumulation: several funds materially increased or initiated positions (AQR, Millennium, Cubist among others), signaling professional investor interest that can support the stock over time.
• Neutral Sentiment: Analyst coverage mixed: TD Cowen has maintained a buy stance while at least one service downgraded Cerus from buy to hold — mixed signals that may limit a clear directional catalyst from the Street.
• Neutral Sentiment: Short‑interest print appears unreliable: a March 9 short‑interest note shows 0 shares and 0.0 days‑to‑cover — likely a reporting or data issue. Treat this as noise until exchanges correct filings.
• Negative Sentiment: Heavy insider selling: multiple executives and directors disclosed sales March 5–9 that meaningfully reduced their holdings (CEO William Greenman sold ~78,187 shares; Director Richard J. Benjamin reported multiple sales; COO Vivek Jayaraman ~34,094; CFO Kevin D. Green ~27,796; plus other insider transactions). The clustered sales (each at roughly $1.88–$2.06) increase float and can weigh on near‑term sentiment even if sales are for personal liquidity. Source example: InsiderTrades coverage of recent filings. Cerus insider selling article
• Negative Sentiment: Analyst downgrade pressure: at least one service downgraded Cerus from buy to hold recently, which can amplify negative reaction to insider sales and slow buying from retail investors.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.